Open menu

Nanoparticles developed to improve magnetic resonance scan images

(Nanowerk News) Researchers at the Chemical Technology Institute (ITQ) of the Unviersitat Politècnica de València and the Spanish Naitonal Research Council (CSIC), the Bioengineering Institute of the Universidad Miguel Hernández (UMH) and the Bioengineering, Biomaterials and Nanomedicine Networking Biomedical Research Group (CIBER-BBN), the Neurosciences Institute (UMH-CSIC) and company Inscanner SL have developed nanoparticles that improve the contrast in magnetic resonance scan images.
Measuring 90 nanometres, their clinical use could facilitate the diagnosis of hepatic, pulmonary and cardiovascular pathologies, as well as many types of tumours. Their work has been published in the Nanoscale journal ("Engineered contrast agents in a single structure for T1–T2 dual magnetic resonance imaging").
As Pablo Botella, head scientist at the CSIC’s Chemical Technology Institute explains, obtaining magnetic resonance images is a clinical diagnosis tool of great importance. “However, obtaining high quality images is usually difficult due to a lack of contrast and other changes associated with the various pathologies that are being studied, which can lead to a loss of sensitivity and complicate the diagnosis.”
In order to tackle these shortcomings, contrast agents based on soluble gadolinium (Gd3+) chelates are commonly administered intravenously. These agents make certain body structures or tissues visually different to how they would be seen if the contrast agent had not been applied. These changes are temporary and facilitate the clinical diagnosis, but the use of these products may not be advisable in some cases, specially in allergic patients or those with kidney problems.
“Furthermore, even though gadolinium improves the positive contrast of the images (clear areas), it hardly affects negative contrast (dark areas). In this sense, the use of a non-soluble form of gadolinium combined with a dark contrast agent would avoid these problems, and this is what we have developed in this project,” explains Botella.

Hybrid nanoparticles

The research team, coordinated by the Nanomedicine group of the ITQ headed by Pablo Botella, has developed hybrid nanoparticles that contain two contrast agents, gadolinium (Gd3+, which increases positive contrast) and iron (Fe3+, which raises negative contrast), protected by a stable silica cover.
The structuring of both magnetic centres in a structure with a high level of bundling leads to a synergic effect which notably increases its magnetic activity, leading to a larger increase of positive and negative contrast in magnetic resonance images compared to commercial products.
Moreover, the cover makes it possible to add molecules that stabilise the particles in physiological environments (such as polyethylene glycol), as well as molecules that will direct the product to a specific therapeutic target.
In this respect, “nanoparticles can selectively accumulate on certain pathological tissues, as long as there is an appropriate guiding molecule. This would be useful for the diagnosis of several types of cancer; we are currently working on its use for prostate cancer, and are obtaining positive results,” adds Botella.
The results obtained in animals makes it possible to clearly observe that after the intravenous administration of this new contrast agent there is a significant improvement of positive and negative contrast in tissues where the nanoparticles accumulate.
On the other hand, says Eduardo Fernández, of the Bioengineering Institute of the UMH and CIBER BBN, “our results suggest that this new type of contrast agents based on hybrid nanoparticles is not toxic for the animals in which it was tested, and the nanoparticles are completely eliminated through biliary and kidney activity, which attests to its great potential.”
“The results obtained on an animal model suggest a variable improvement depending on the tissue, of up to 78% of the signal intensity in magnetic resonance images, making clinical diagnosis easier,” concludes Pablo Botella. The signal intensity increase involves a raise in contrast, which in turn improves resolution, allowing the radiologist to clearly differentiate between pathological tissue and background noise.
Source: Asociación RUVID
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
 
These articles might interest you as well: